Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Acrivon Therapeutics approved a grant of 111,150 stock options to one new employee under its 2023 Inducement Plan. The grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment.
Key figures
- Grant type
- stock options
- Shares granted
- 111150
- Vesting schedule
- 25% after 1 year, then monthly 2.083%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.